Camlin Fine Sciences
149.98
-4.09(-2.65%)
Market Cap₹2,819.33 Cr
PE Ratio-90.26
IndustryChemicals
Company Performance:
1D-2.65%
1M-23.37%
6M-31.04%
1Y+31.93%
5Y+49.55%
View Company Insightsright
More news about Camlin Fine Sciences
24Sept 25
Camlin Fine Sciences to Consider Preferential Share Allotment for Vinpai Acquisition
Camlin Fine Sciences Limited has scheduled a board meeting on September 29, 2025, to consider issuing equity shares through preferential allotment as part of a share swap to acquire a majority stake in Vinpai S.A. The company has implemented a trading window closure from September 24, 2025, until 48 hours after the board meeting concludes. If approved, the proposal will be subject to shareholder approval via postal ballot. The move aligns with the company's strategic plans disclosed earlier in 2025.
08Aug 25
Camlin Fine Sciences Reports Narrowed Q1 Loss Despite Revenue Dip
Camlin Fine Sciences reported a consolidated net loss of 100 million rupees in Q1, down from 340 million rupees last year, despite revenue falling to 4,236 million rupees from 4,375 million rupees. The Specialty Ingredients (Value-added Blends) segment showed strong growth, while other segments experienced declines. EBITDA decreased to 190 million rupees, with the margin contracting to 4.49%. Regional performance varied, with Mexico and Europe showing growth. The company is focusing on high-value blends and additives, developing new downstream products, and enhancing its naturals and emulsifiers portfolio.
23May 25
Camlin Fine Sciences Reports Improved Q4 EBITDA and Margin, Narrows Losses
Camlin Fine Sciences Ltd. has reported a substantial improvement in its Q4 financial results. The company reduced its net loss to ₹7.00 million from ₹771.00 million year-over-year. Revenue increased by 14.47% to ₹4.35 billion, while EBITDA rose to ₹594.00 million with an improved margin of 13.66%. The company also showed better expense management, with total expenses decreasing by 27.19% quarter-on-quarter.
27Feb 25
Camlin Fine Sciences to Expand Portfolio with Majority Stake Acquisition in Vinpai
Camlin Fine Sciences Ltd (CFSL) plans to acquire a majority stake in Vinpai through a share swap arrangement. The deal values Vinpai shares at €3.60 each. This strategic move aims to expand CFSL's product portfolio and market reach in the specialty chemicals industry. The acquisition is expected to bring portfolio expansion, increased market reach, potential synergies, and enhanced innovation capabilities for CFSL.
25Feb 25
Camlin Fine Sciences to Acquire Up to 100% Stake in French Ingredient-Tech Company Vinpai S.A.
Camlin Fine Sciences Limited (CFS) plans to acquire up to 100% stake in Vinpai S.A., a French ingredient-tech company specializing in natural alternatives to chemical additives. The acquisition involves a multi-step process including a share purchase agreement for a 78.68% stake, a €3.3 million convertible bond investment, and a potential mandatory tender offer for remaining shares. The total acquisition cost could reach €5.96 million. This strategic move aims to expand CFS's product portfolio, access new technologies, and strengthen its position in the food, cosmetics, and nutraceutical industries. Vinpai, founded in 2011, has shown consistent growth with a projected turnover of €9.2 million in 2024.
Camlin Fine Sciences
149.98
-4.09
(-2.65%)
1 Year Returns:+31.93%
Industry Peers
Pidilite Industries
1,463.00
(-0.62%)
SRF
2,807.50
(-1.09%)
Gujarat Fluorochemicals
3,395.50
(-2.46%)
Deepak Nitrite
1,625.30
(-3.93%)
BASF
4,244.20
(-3.44%)
Atul
5,920.50
(-0.85%)
Vinati Organics
1,611.10
(+1.03%)
Aarti Industries
380.80
(-1.03%)